| ²é¿´: 200 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
zhangjx7880ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
|
[½»Á÷]
¡¾×ªÌû¡¿3ÖÖ¼¤Ã¸Óë°¢¶û´Äº£Ä¬²¡·¢²¡Ïà¹Ø
|
||
|
ÃÀ¹úתÒëÒÅ´«Ñо¿Ëù£¨TGen£©µÄÒ»¿ÆÑ§Ð¡×é·¢ÏÖÁË3ÖÖ¿ÉÒý·¢taoµ°°×¹¦ÄÜÕϰµÄ¼¤Ã¸£¨´Ó¸ßÄܹ©Ìå·Ö×Ó×ªÒÆÁ×Ëá»ùÍŵ½Ìض¨°Ð·Ö×ӵĸ£©£¬ÕýÊÇÕâ3ÖÖ¼¤Ã¸×è¶ÏÁË´óÄÔϸ°û¼äµÄÁ¬½Ó£¬½ø¶øµ¼ÖÂÁËÓë°¢¶û´Äº£Ä¬²¡Ïà¹ØµÄ¼ÇÒäȱʧÎÊÌâ¡£Ñо¿ÈËÔ±ÈÏΪ£¬¸Ã·¢ÏÖÓÐÖúÓÚ¿ª·¢³öÖÎÁư¢¶û´Äº£Ä¬²¡µÄÐÂÒ©¡£Ïà¹ØÂÛÎÄ·¢±íÔÚ½üÆÚ³ö°æµÄ¡¶BMC»ùÒò×éѧ¡·ÔÓÖ¾ÉÏ¡£ taoµ°°×ÊÇÒ»ÖÖ¶ÔÉñ¾Ï¸°û¼ä΢¹ÜÁ¬½ÓÇŵÄÐÎ³ÉÆðÖØÒª×÷Óõĵ°°×¡£ÕâÖÖ΢¹ÜÇÅÓÌÈçÉñ¾Ï¸°ûÄڵġ°¹Ç¼Ü¡±£¬Ö§³Ö×ÅÍ»´¥Á¬½Ó£¬Ê¹Éñ¾Ï¸°û¼äÈç¼ÆËã»úµç·һÑùÄܱ˴˹µÍ¨¡£Èç¹ûtaoµ°°×¹¦ÄܳöÏÖÕϰ£¬½«µ¼ÖÂÉñ¾Ï¸°û¼äÎÞ·¨ÔÙÏ໥ÁªÏµ£¬´Ó¶øÑÏÖØÓ°ÏìÈ˵ÄÈÏÖª£¬¼´Ë¼¿¼ºÍÍÆÀíÄÜÁ¦¡£ TGenÉñ¾±äÐÔÑо¿Ð¡×éÖúÀíÑо¿Ô±ÌØÀά˹¡¤µË¿ËÀû²©Ê¿×«ÎÄÖ¸³ö£¬ÔÚÕý³£Çé¿öÏ£¬¼¤Ã¸Í¨¹ýÔö¼ÓÁ×ËáÀ´µ÷½Útaoµ°°×£¬Õâ¸ö±»½Ð×ötaoµ°°×Á×ËữµÄ¹ý³Ì¿Éʹ΢¹Ü½â¿ªºóÔٰ󶨣¬Ê¹Éñ¾Ï¸°û¼äÄܹ»Ï໥Á¬½Ó£¬´Ó¶ø´Ù½øÈ˵ļÇÒäµÄÐγɺͱ£³Ö¡£ È»¶ø£¬ÓÐʱtaoµ°°×»á¹ý¶ÈÁ×Ëữ£¬Î¢¹ÜÇŻᱻ²ð½â£¬µ¼ÖÂÉñ¾ÔÏËά²ø½á¡£¶øÉñ¾ÔÏËά²ø½áÊǰ¢¶û´Äº£Ä¬²¡µÄµäÐͲ¡ÀíÌØÕ÷Ö®Ò»¡£ ¸ÃÑо¿Ð¡×éʹÓÃÒ»ÖÖ½Ð×ösiRNAµÄ·Ö×Ó¹¤¾ß£¬¶ÔÈËÌåϸ°ûÄÚËùÓÐÒÑÖªµÄºÍÀíÂÛÍÆÀí³öµÄ572¸ö¼¤Ã¸½øÐÐÁ˸´ÔӵIJâÊÔ£¬×îÖÕÈ·¶¨ÁË26¸öÓëtaoµ°°×Á×ËữÓйصļ¤Ã¸£¬¶øÆäÖеÄ3ÖÖ¼¤Ã¸EIF2AK2¡¢DYRK1AºÍAKAP13µ¼ÖÂÁËtaoµ°°×µÄ¹ý¶ÈÁ×Ëữ£¬´Ó¶øÓÀ¾ÃµØ²ð½âÁË΢¹ÜÇÅ¡£ TGenÉñ¾ÒÅ´«Ñ§·Ö²¿µÄÁÙ´²Ö÷ÈΣ¬Í¬Ê±Ò²ÊǰÍÄɰ¢¶û´Äº£Ä¬²¡Ñо¿ËùÖ´ÐÐÖ÷Èεİ£Àï¿Ë¡¤À×Âü²©Ê¿½âÊÍ˵£¬taoµ°°×½«Éñ¾Ï¸°ûÄڵġ°¹Ç¼Ü¡±½áºÏÔÚÒ»Æð£¬µ±Á×Ëá·Ö×ÓÓëtaoµ°°×Õ³ºÏʱ£¬¸Ã¡°¹Ç¼Ü¡±Í߽⣬Éñ¾Ï¸°û¿ªÊ¼ÊÕ»ØÍ»´¥·ÖÖ§²¢ËÀÍö£¬µ¼Ö¼ÇÒäɥʧºÍ˼¿¼ÄÜÁ¦³öÏÖÎÊÌâ¡£¶øÍ¨¹ýsiRNA£¬Ñо¿ÈËÔ±¾Í¿É¶Ï¶¨£¬ÊÇÄÄÒ»ÖÖµ°°×´Ù·¢ÁËÁ×Ëá·Ö×ÓÓëtaoµ°°×µÄÕ³½á¡£ À×Âü³Æ£¬Õâ3ÖÖ¼¤Ã¸ÏÖÔÚ»ò¿É³ÉΪµ°°×ÒÖÖÆÒ©ÎïµÄ°Ðµã¡£Èç¹ûÄÜ¿ª·¢³öÒ»ÖÖ°²È«µÄ¡¢ÄÍÊÜÐԺܺõÄÖÎÁÆÉñ¾ÔÏËά²ø½áµÄÒ©Î½«¸ø°¢¶û´Äº£Ä¬²¡µÄÖÎÁÆ´øÀ´Ï£Íû¡£ËûÃÇÏÂÒ»²½µÄÈÎÎñ£¬¾ÍÊÇÒªÕÒµ½²¢È·¶¨Ê¹Õâ3ÖÖ¼¤Ã¸ÎÞЧµÄÒ©Îï³É·Ö¡£ |
» ²ÂÄãϲ»¶
ͶÃϵ¶ûËæ»ú»¯µÄÎÄÕÂ
ÒѾÓÐ2È˻ظ´
´ïÍÐÃ¹ËØÔÓÖÊ61
ÒѾÓÐ0È˻ظ´
ÖÐҩѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ181È˻ظ´
°¢Î¬¾úËØÔÓÖÊ3(°¢Î¬¾úËØA2a)
ÒѾÓÐ0È˻ظ´
°¢Î¬¾úËØ
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Áò°·ËØÔÓÖÊ93
ÒѾÓÐ0È˻ظ´
340Çóµ÷¼Á£¨Ò»Ö¾Ô¸£ºÁÙ¼ìѧ˶£©
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
zhangjx7880
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 14693.7
- ºì»¨: 2
- ɳ·¢: 1
- Ìû×Ó: 3631
- ÔÚÏß: 96.5Сʱ
- ³æºÅ: 603348
- ×¢²á: 2008-09-15
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
|
BMC Genomics 2010, 11:25doi:10.1186/1471-2164-11-25 High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation David O Azorsa , RiLee H Robeson , Danielle Frost , Bessie Meechoovet , Gillian R Brautigam , Chad Dickey , Christian Beaudry , Gargi D Basu , David R Holz , Joseph A Hernandez , Kristen M Bisanz , Leslie Gwinn , Andrew Grover , Joseph Rogers , Eric M Reiman , Michael Hutton , Dietrich A Stephan , Spyro Mousses and Travis Dunckley Background Neurofibrillary tangles (NFT), a cardinal neuropathological feature of Alzheimer's disease (AD) that is highly correlated with synaptic loss and dementia severity, appear to be partly attributable to increased phosphorylation of the microtubule stabilizing protein tau at certain AD-related residues. Identifying the kinases involved in the pathologic phosphorylation of tau may provide targets at which to aim new AD-modifying treatments. Results We report results from a screen of 572 kinases in the human genome for effects on tau hyperphosphorylation using a loss of function, high-throughput RNAi approach. We confirm effects of three kinases from this screen, the eukaryotic translation initiation factor 2 kinase 2 (EIF2AK2), the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A), and the A-kinase anchor protein 13 (AKAP13) on tau phosphorylation at serine 262. We provide evidence that EIF2AK2 effects may result from effects on tau protein expression, whereas DYRK1A and AKAP13 are likely more specifically involved in tau phosphorylation pathways. Conclusions These findings identify novel kinases that phosphorylate tau protein and provide a valuable reference data set describing the kinases involved in phosphorylating tau at an AD-relevant epitope. |
2Â¥2010-01-25 04:46:02














»Ø¸´´ËÂ¥